Brief: FDA Approves Use Of Voyxact To Reduce Proteinuria In Primary Immunoglobulin
25/11/2025 20:10
Nov 26 (Reuters) - FDA: FDA - APPROVED USE OF VOYXACT TO REDUCE PROTEINURIA IN PRIMARY IMMUNOGLOBULIN Further company coverage: 4578.T ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug